Condition: Advanced Solid Tumor · Metastatic Solid Tumor · Refractory Solid Tumor · Sponsor: Circle Pharma
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
This description comes directly from the study's public registry record.
Lisa Kopp, DO, MPH · 1-877-648-8777 · CID078ClinicalTrials@circlepharma.com
Always discuss trial participation with your own doctor first.
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Comprehensive Cancer Centers of Nevada | Las Vegas, Nevada, United States | Recruiting |
| UH Seidman Cancer Center | Cleveland, Ohio, United States | Recruiting |
| Oregon Health and Science University | Portland, Oregon, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| START Mountain | West Valley City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06577987